R Kannan Mutharasan
Overview
Explore the profile of R Kannan Mutharasan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Philbin S, Gleason L, Persell S, Walter E, Petito L, Tibrewala A, et al.
medRxiv
. 2024 Nov;
PMID: 39574854
Background: Clinical guidelines recommend medications from four drug classes, collectively referred to as quadruple therapy, to improve outcomes for patients with heart failure with reduced ejection fraction (HFrEF). Wide gaps...
2.
3.
Ahmad F, Hu T, Adler E, Petito L, Wehbe R, Wilcox J, et al.
Clin Res Cardiol
. 2024 Apr;
113(9):1343-1354.
PMID: 38565710
Background: Referral of patients with heart failure (HF) who are at high mortality risk for specialist evaluation is recommended. Yet, most tools for identifying such patients are difficult to implement...
4.
Bailey J, Lavelle B, Miller J, Jimenez M, Lim P, Orban Z, et al.
Am J Med
. 2023 May;
138(1):108-120.
PMID: 37220832
Background: Persistent multi-organ symptoms after coronavirus disease 2019 (COVID-19) have been termed "long COVID" or "post-acute sequelae of SARS-CoV-2 infection." The complexity of these clinical manifestations posed challenges early in...
5.
Cheema B, Mutharasan R, Sharma A, Jacobs M, Powers K, Lehrer S, et al.
JACC Adv
. 2023 Jan;
1(4).
PMID: 36643021
Background: Timely referral for specialist evaluation in patients with advanced heart failure (HF) is a Class 1 recommendation. However, the transition from stage C HF to advanced or stage D...
6.
Gay H, Yu J, Persell S, Linder J, Srivastava A, Isakova T, et al.
Am J Cardiol
. 2022 Nov;
189:121-130.
PMID: 36424193
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) reduce cardiovascular events and mortality in patients with type 2 diabetes mellitus (T2DM). We sought to describe trends in prescribing...
7.
Hughes Z, Simkowski J, Mendapara P, Fink N, Gupta S, Youmans Q, et al.
JMIR Cardio
. 2022 Nov;
6(2):e39566.
PMID: 36409959
Background: Low rates of heart failure (HF) hospitalizations were observed during the 2020 peak of the COVID-19 pandemic. Additionally, posthospitalization follow-up transitioned to a predominantly telemedicine model. It is unknown...
8.
Shah K, Reyes-Miranda A, Bradley S, Breathett K, Das S, Gluckman T, et al.
J Racial Ethn Health Disparities
. 2022 Apr;
10(2):892-898.
PMID: 35380371
As COVID-19 cases begin to decrease in the USA, learning from the pandemic experience will provide insights regarding disparities of care delivery. We sought to determine if specific populations hospitalized...
9.
Bradley S, Emmons-Bell S, Mutharasan R, Rodriguez F, Gupta D, Roth G, et al.
Sci Rep
. 2021 Jul;
11(1):15097.
PMID: 34302004
There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957...
10.
Bradley S, Adusumalli S, Amin A, Borden W, Das S, Downey W, et al.
Circ Cardiovasc Qual Outcomes
. 2021 Jan;
14(1):e006753.
PMID: 33430610
Despite decades of improvement in the quality and outcomes of cardiovascular care, significant gaps remain. Existing quality improvement strategies are often limited in scope to specific clinical conditions and episodic...